Related Experiment Video
Updated: Dec 26, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple
Eric H Yang1, Cynthia Courtney2, Vinisha Garg1
11UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine UCLA Cardiovascular Center, 100 Medical Plaza, Suite 630, Los Angeles, CA 90095 USA.
Abstract:
Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed multiple myeloma (MM). However, there are reports of adverse cardiac events with carfilzomib manifested by dyspnea and heart failure. A patient is presented who had recurrent, clinically mild cardiotoxicity, as manifested by recurrent heart failure with preserved ejection fraction, with ongoing maintenance carfilzomib in a patient with resistant MM is presented.
More Related Videos
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure III: Clinical Manifestations
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Cardiomyopathy III: Hypertrophic Cardiomyopathy

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)